Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
As of close of business last night, Catalyst Pharmaceuticals Inc’s stock clocked out at $23.15, down -0.81% from its previous closing price of $23.34. In other words, the price has decreased by -$0.81 from its previous closing price. On the day, 0.82 million shares were traded. CPRX stock price reached its highest trading level at $23.54 during the session, while it also had its lowest trading level at $22.93.
Ratios:
To gain a deeper understanding of CPRX’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.12 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 12.13. For the most recent quarter (mrq), Quick Ratio is recorded 6.40 and its Current Ratio is at 6.62. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In the most recent recommendation for this company, Robert W. Baird on February 04, 2025, initiated with a Outperform rating and assigned the stock a target price of $28.
On November 18, 2024, Stephens started tracking the stock assigning a Overweight rating and target price of $35.
On March 14, 2024, Citigroup started tracking the stock assigning a Buy rating and target price of $27.Citigroup initiated its Buy rating on March 14, 2024, with a $27 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 12 ’25 when Harper Molly sold 26,746 shares for $23.25 per share. The transaction valued at 621,920 led to the insider holds 2,360 shares of the business.
Harper Molly bought 26,746 shares of CPRX for $621,929 on Dec 12 ’25. On Nov 26 ’25, another insider, Del Carmen Jeffrey, who serves as the Chief Commercial Officer of the company, sold 10,983 shares for $23.33 each. As a result, the insider received 256,244 and left with 3,962 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CPRX now has a Market Capitalization of 2845421568 and an Enterprise Value of 2158418688. As of this moment, Catalyst’s Price-to-Earnings (P/E) ratio for their current fiscal year is 13.51, and their Forward P/E ratio for the next fiscal year is 12.96. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.10. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.92 while its Price-to-Book (P/B) ratio in mrq is 3.10. Its current Enterprise Value per Revenue stands at 3.733 whereas that against EBITDA is 7.278.
Stock Price History:
The Beta on a monthly basis for CPRX is 0.72, which has changed by 0.14660728 over the last 52 weeks, in comparison to a change of 0.14778805 over the same period for the S&P500. Over the past 52 weeks, CPRX has reached a high of $26.58, while it has fallen to a 52-week low of $19.05. The 50-Day Moving Average of the stock is 1.75%, while the 200-Day Moving Average is calculated to be 4.07%.
Shares Statistics:
It appears that CPRX traded 1.33M shares on average per day over the past three months and 1037170 shares per day over the past ten days. A total of 123.26M shares are outstanding, with a floating share count of 110.40M. Insiders hold about 10.14% of the company’s shares, while institutions hold 81.02% stake in the company. Shares short for CPRX as of 1765756800 were 7896866 with a Short Ratio of 5.92, compared to 1763078400 on 8487702. Therefore, it implies a Short% of Shares Outstanding of 7896866 and a Short% of Float of 8.1999995.
Earnings Estimates
The firm’s stock currently is rated by 4.0 analysts. The consensus estimate for the next quarter is $0.59, with high estimates of $0.64 and low estimates of $0.53. Analysts are recommending an EPS of between $2.7 and $2.11 for the fiscal current year, implying an average EPS of $2.5. EPS for the following year is $2.58, with 4.0 analysts recommending between $2.7 and $2.47.
Revenue Estimates
In. The current quarter, 7 analysts expect revenue to total $141.49M. It ranges from a high estimate of $149.64M to a low estimate of $136.14M. As of. The current estimate, Catalyst Pharmaceuticals Inc’s year-ago sales were $141.82MFor the next quarter, 7 analysts are estimating revenue of $142.4M. There is a high estimate of $144.18M for the next quarter, whereas the lowest estimate is $139.5M.
A total of 7 analysts have provided revenue estimates for CPRX’s current fiscal year. The highest revenue estimate was $586.02M, while the lowest revenue estimate was $572.52M, resulting in an average revenue estimate of $577.87M. In the same quarter a year ago, actual revenue was $491.73MBased on 7 analysts’ estimates, the company’s revenue will be $619.51M in the next fiscal year. The high estimate is $633.67M and the low estimate is $595.52M.
